Michael King
Stock Analyst at EF Hutton
(0.90)
# 3,960
Out of 5,123 analysts
107
Total ratings
37.17%
Success rate
-10.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $18.60 | +3,394.62% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $2.56 | +329.69% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.14 | +2,707.02% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.27 | +5,293.70% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $10.61 | +1,785.01% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.61 | +1,269.64% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $766.63 | +12.44% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $42.37 | -43.36% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $2.77 | +5,892.78% | 8 | Mar 28, 2023 | |
| XNCR Xencor | Reiterates: Buy | $42 | $10.82 | +288.17% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $331.24 | -8.22% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $11.09 | +945.99% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.22 | +65.59% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $44.45 | -46.01% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $47.90 | -3.97% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $26.57 | +261.31% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.52 | +6,824.41% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $35.70 | -13.17% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $820.31 | -95.61% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $18.60
Upside: +3,394.62%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $2.56
Upside: +329.69%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.14
Upside: +2,707.02%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.27
Upside: +5,293.70%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $10.61
Upside: +1,785.01%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.61
Upside: +1,269.64%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $766.63
Upside: +12.44%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $42.37
Upside: -43.36%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $2.77
Upside: +5,892.78%
Xencor
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $10.82
Upside: +288.17%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $331.24
Upside: -8.22%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $11.09
Upside: +945.99%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $6.22
Upside: +65.59%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $44.45
Upside: -46.01%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $47.90
Upside: -3.97%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $26.57
Upside: +261.31%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.52
Upside: +6,824.41%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $35.70
Upside: -13.17%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $820.31
Upside: -95.61%